This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.

Inclusion Criteria:

1. Healthy Japanese or white male and female participants aged between 18 and 45 years at the time of consent.
2. Participants who agree to use contraception during a specified period.
3. Participants with a Body Mass Index (BMI) of at least 18.0 kg/m2 and less than 32.0 kg/m2.
4. Participants who are judged to be healthy by the principal (or sub-) investigator.
5. Participants must understand the methods and compliance requirements of this study and must give his/her free and voluntary written consent to participate in this study.

Exclusion Criteria:

1. Participants with clinically relevant symptoms, diseases, or pre-existing conditions.
2. Participants with extensive skin findings on the abdomen.
3. Participant who has used or will use prescription drugs, non-prescription drugs or products containing herbal medicines within a specified period
4. Participants whose normal weekly alcohol intake exceeds 150 g.
5. Habitual consumers of caffeine-containing beverages who are likely to experience symptoms if they stop.
6. Smokers or those who have smoked or used other nicotine-containing products within 6 months.
7. Participants who participated in a clinical trial and took a new active pharmacological ingredient within a specified period.
8. Participants who have undergone surgery within 4 weeks.
9. Pregnant or lactating women.